" class="no-js "lang="en-US"> Transgene - Medtech Alert
Thursday, March 30, 2023

Breaking News

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Implantica Launches RefluxStop™ in Italy Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases Xeris Biopharma Appoints Ricki Fairley to Board of Directors AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease New Imaging Method for Evaluating Transport of Oxygen to Blood Cells
Transgene | Pharmtech Focus

Transgene

About Transgene

Transgene

Cancer immunotherapy

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing novel immunotherapies for the treatment of cancer.

Related Story

News

 Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors | MTA

Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors

March 10 2023

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, […]

Diseases

 Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050

Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine

November 23 2021

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment […]